Madrigal Pharmaceuticals focuses on treating metabolic dysfunction-associated steatohepatitis (MASH) with its drug Rezdiffra, which has a growing U.S. market potential. The company benefits from a first-mover advantage but faces long-term competition from drugs like Novo Nordisk’s Wegovy and Efruxifermin. Analysts rate Madrigal as a Buy, expecting strong growth over the next 2-3 years, while advising caution due to potential stock volatility and recommending careful position sizing around $400 per share.
DBV Technologies has begun screening the first participant in its phase 2 THRIVE clinical trial to test the VIASKIN Peanut patch on infants aged 6 to 12 months with peanut allergies. The study aims to evaluate the patch's safety and effectiveness in ...
Robbins LLP is investigating Beta Bionics, Inc.'s officers and directors for potential violations of securities laws and breaches of fiduciary duties following the company's announcement of weaker-than-expected patient growth. Beta Bionics reported a...
Robbins LLP is investigating whether officers and directors of Simulation Plus, Inc. violated securities laws and breached fiduciary duties following significant stock price drops in 2025. The company faced a 24% stock decline after lowering revenue ...
Canada is in a technical recession with economic contraction in three of the last four quarters, the worst among G7 nations. Entrepreneur Yanik Guillemette criticizes Ottawa's weak leadership and decision paralysis, which erodes business confidence a...
A South African High Court ruled that sending Bitcoin to overseas exchanges counts as a capital export, subjecting such transfers to the country's foreign exchange control regulations. This means South African residents must comply with exchange cont...
